Insider Transactions in Q1 2022 at Cytokinetics Inc (CYTK)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 21
2022
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
10,000
-2.39%
|
$360,000
$36.03 P/Share
|
|
Mar 21
2022
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.33%
|
$70,000
$7.96 P/Share
|
|
Mar 15
2022
|
Mark A Schlossberg SVP - Legal & General Counsel |
SELL
Open market or private sale
|
Direct |
25,196
-19.59%
|
$831,468
$33.96 P/Share
|
|
Mar 15
2022
|
Mark A Schlossberg SVP - Legal & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
60,817
+14.88%
|
$668,987
$11.94 P/Share
|
|
Mar 10
2022
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
26,852
-13.77%
|
$993,524
$37.82 P/Share
|
|
Mar 10
2022
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
26,852
+12.11%
|
$161,112
$6.0 P/Share
|
|
Mar 09
2022
|
Ching Jaw SVP Finance & CFO |
SELL
Open market or private sale
|
Direct |
15,000
-18.27%
|
$570,000
$38.0 P/Share
|
|
Mar 09
2022
|
Ching Jaw SVP Finance & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+15.45%
|
$180,000
$12.1 P/Share
|
|
Mar 07
2022
|
Robert I Blum President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
23,799
-5.5%
|
$856,764
$36.83 P/Share
|
|
Mar 07
2022
|
David Cragg Chief HR & Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,399
-3.4%
|
$194,364
$36.83 P/Share
|
|
Mar 07
2022
|
Ching Jaw SVP Finance & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,510
-7.59%
|
$198,360
$36.83 P/Share
|
|
Mar 07
2022
|
Fady Ibraham Malik EVP Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
9,916
-5.57%
|
$356,976
$36.83 P/Share
|
|
Mar 07
2022
|
Mark A Schlossberg SVP - Legal & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
4,631
-6.39%
|
$166,716
$36.83 P/Share
|
|
Mar 07
2022
|
Robert Wong VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,384
-4.15%
|
$49,824
$36.83 P/Share
|
|
Mar 02
2022
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
10,000
-2.26%
|
$360,000
$36.31 P/Share
|
|
Mar 02
2022
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.21%
|
$70,000
$7.96 P/Share
|
|
Mar 02
2022
|
Andrew Callos EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+43.29%
|
-
|
|
Mar 02
2022
|
Robert I Blum President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+16.41%
|
-
|
|
Mar 02
2022
|
Robert I Blum President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
15,866
-4.36%
|
$587,042
$37.63 P/Share
|
|
Mar 02
2022
|
David Cragg Chief HR & Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+11.2%
|
-
|
|
Mar 02
2022
|
David Cragg Chief HR & Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,458
-2.43%
|
$127,946
$37.63 P/Share
|
|
Mar 02
2022
|
Ching Jaw SVP Finance & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+21.59%
|
-
|
|
Mar 02
2022
|
Ching Jaw SVP Finance & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,458
-6.17%
|
$127,946
$37.63 P/Share
|
|
Mar 02
2022
|
Fady Ibraham Malik EVP Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+14.42%
|
-
|
|
Mar 02
2022
|
Fady Ibraham Malik EVP Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
5,004
-3.27%
|
$185,148
$37.63 P/Share
|
|
Mar 02
2022
|
Mark A Schlossberg SVP - Legal & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+21.64%
|
-
|
|
Mar 02
2022
|
Mark A Schlossberg SVP - Legal & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,457
-6.19%
|
$127,909
$37.63 P/Share
|
|
Mar 02
2022
|
Robert Wong VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+18.36%
|
-
|
|
Mar 02
2022
|
Robert Wong VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,447
-5.3%
|
$53,539
$37.63 P/Share
|
|
Mar 02
2022
|
Santo J Costa Director |
SELL
Open market or private sale
|
Direct |
10,000
-66.67%
|
$370,000
$37.35 P/Share
|
|
Mar 02
2022
|
Santo J Costa Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+40.0%
|
$100,000
$10.68 P/Share
|
|
Mar 01
2022
|
John T Henderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,166
+18.73%
|
$20,830
$5.46 P/Share
|
|
Feb 28
2022
|
Robert I Blum President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,329
-3.02%
|
$396,515
$35.32 P/Share
|
|
Feb 28
2022
|
David Cragg Chief HR & Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,071
-1.44%
|
$72,485
$35.32 P/Share
|
|
Feb 28
2022
|
Ching Jaw SVP Finance & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,074
-3.57%
|
$72,590
$35.32 P/Share
|
|
Feb 28
2022
|
Fady Ibraham Malik EVP Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
3,458
-2.21%
|
$121,030
$35.32 P/Share
|
|
Feb 16
2022
|
Robert I Blum President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
14,474
+1.91%
|
-
|
|
Feb 16
2022
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
10,000
-2.7%
|
$360,000
$36.5 P/Share
|
|
Feb 16
2022
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.63%
|
$70,000
$7.96 P/Share
|
|
Feb 16
2022
|
Andrew Callos EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,044
+35.99%
|
-
|
|
Feb 16
2022
|
David Cragg Chief HR & Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,008
+1.72%
|
-
|
|
Feb 16
2022
|
Ching Jaw SVP Finance & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
5,022
+4.22%
|
-
|
|
Feb 16
2022
|
Fady Ibraham Malik EVP Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
7,148
+2.26%
|
-
|
|
Feb 16
2022
|
Mark A Schlossberg SVP - Legal & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
5,025
+4.39%
|
-
|
|
Feb 16
2022
|
Robert Wong VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,987
+3.57%
|
-
|
|
Feb 07
2022
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
10,000
-2.7%
|
$330,000
$33.86 P/Share
|
|
Feb 07
2022
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.63%
|
$70,000
$7.96 P/Share
|
|
Jan 03
2022
|
Muna Bhanji Director |
BUY
Grant, award, or other acquisition
|
Direct |
244
+4.45%
|
$11,224
$46.0 P/Share
|
|
Jan 03
2022
|
Robert Califf Director |
BUY
Grant, award, or other acquisition
|
Direct |
122
+1.99%
|
$5,612
$46.0 P/Share
|
|
Jan 03
2022
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
244
+1.78%
|
$11,224
$46.0 P/Share
|